Matthias Alder insider trades: Gain Therapeutics (GANX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthias reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 21, 2023 | GANX | ↓ Sell | 206 | $2.46 | $507 | Direct | Dec 22, 2023 (1d) |
| Dec 7, 2023 | GANX | ↓ Sell | 1,820 | $2.50 | $5K | Direct | Dec 14, 2023 (7d) |
| Nov 28, 2016 | SCMP | ↓ Sell | 150,000 | $16.00 | $2.4M | Direct | Nov 28, 2016 (0d) |
| Jan 25, 2010 | MITI | ↓ Sell | 10,000 | $8.25 | $83K | Direct | Jan 27, 2010 (2d) |
| Jan 19, 2010 | MITI | ↓ Sell | 10,000 | $7.16 | $72K | Direct | Jan 21, 2010 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Matthias Alder's insider trades
Matthias Alder is Chief Executive Officer at Gain Therapeutics (GANX). Since Jan 19, 2010, Matthias has reported no open-market purchases and 5 sales worth $2.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (23 filings), option exercises (8 filings), shares withheld for taxes (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GANX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.